Results 211 to 220 of about 80,637 (252)

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma. [PDF]

J Immunother Cancer
McKay RR, Serzan M, Xie W, McGregor BA, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan BL, Rose T, Stadler WM, Mcdermott DF, Choueiri TK.   +12 more
europepmc   +1 more source

Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice

BJU International, Volume 138, Issue 4, Page 558-564, October 2026.
Objectives To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle‐invasive bladder cancer (MIBC), and to determine whether trial‐derived evidence can inform response evaluation in contemporary practice. Subjects/Patients and Methods We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for ...
Roberto Contieri, Bas W.G. van Rhijn, Richard Cathomas, Anja Lorch, Daniela Oprea‐Lager, Paramananthan Mariappan, Francesco Sanguedolce, Antoine G. van der Heijden, Laura S. Mertens, In collaboration with the EAU Imaging Section   +9 more
wiley   +1 more source

Immune checkpoint inhibitor-associated eosinophilic fasciitis: a systematic review of reported cases. [PDF]

An Bras Dermatol
Argobi Y, Tobeigei F, Alasiri FI.
europepmc   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. [PDF]

Hum Vaccin Immunother
Yan C, Li Z, Zhao Q, Gao Y, Li J, Diao R.   +5 more
europepmc   +1 more source

The evolving role of immunotherapy in ovarian cancer

Cancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani, Laura Venegas, Amit M. Oza   +2 more
wiley   +1 more source

The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Jiang Q, Liu J, Li Z, Zhang C, Dang Q, Tian Y.   +5 more
europepmc   +1 more source

Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot, Mathieu Corvaisier, Laurence Spiesser‐Robelet, Mylène Duplan, Isabelle Pellier, Delphine Bourneau‐Martin, Séverine Derbré   +6 more
wiley   +1 more source

Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study. [PDF]

Immunotargets Ther
Yokouchi H, Nishihara H, Kenmotsu Y, Tsuji K, Kishikawa T, Kikuchi H, Miyauchi E, Nagano Y, Kanazawa K, Sugisaka J, Ohkuri T, Oizumi S.   +11 more
europepmc   +1 more source